Candidate Selection Services
Select a Development Candidate with Confidence
Candidate selection begins when lead optimization has produced a small number of candidates that meet the program’s core requirements. At this stage, the objective is no longer to iteratively improve individual leads, but to compare the totality of evidence, resolve decision-critical uncertainties, and nominate the candidate with the strongest overall potential for preclinical development.
WuXi Biology and Testing integrates discovery biology, in vivo pharmacology, DMPK, bioanalysis, and early safety assessment to compare candidates, identify critical data gaps, and support evidence-based progression into IND-enabling studies. Our cross-functional teams can tailor the strategy to the therapeutic modality, disease biology, route of administration, and stage-specific program risks.
From Optimized Leads to a Defensible Nomination
A fit-for-purpose candidate selection framework brings decision-critical evidence together to:
- Establish predefined candidate nomination criteria
- Compare shortlisted candidates on a consistent basis
- Confirm the reproducibility of key findings
- Evaluate exposure-efficacy and exposure-safety margins
- Resolve conflicting or incomplete datasets
- Identify remaining risks and IND-enabling data gaps
- Document the rationale for selecting the primary and backup candidates
Together, these elements support a transparent, evidence-based nomination decision and a focused transition into IND-enabling development.
Establish Translational Confidence and Exposure Margins
Integrated pharmacology, PK/PD, and bioanalytical data help determine whether the observed efficacy is supported by achievable systemic or tissue exposure. Candidate comparison should consider target engagement, biomarker response, duration of activity, cross-species pharmacokinetics, and the exposure associated with the desired pharmacological effect.
Early safety and tolerability findings can then be evaluated relative to pharmacologically active exposure. These exposure-efficacy and exposure-safety relationships provide a stronger basis for candidate nomination than potency or exposure alone.
Define IND-Enabling Readiness and Next Steps
Before nomination, remaining scientific and operational risks should be translated into a clear development plan. This may include identifying additional data needs, selecting relevant species, evaluating formulation and route-of-administration feasibility, establishing bioanalytical and biomarker strategies, and planning definitive pharmacology and toxicology studies.
The result is not simply a selected candidate, but a documented nomination rationale, a risk-mitigation strategy, and a coordinated roadmap for IND-enabling development.
Related Services
Explore the integrated capabilities that support evidence-based candidate nomination and progression into IND-enabling development.
Discovery Biology
Confirm mechanism, potency, selectivity, target engagement, and efficacy in relevant biological models.
Learn More
DMPK
Characterize ADME, exposure, tissue distribution, and PK/PD relationships across relevant species.
Learn More
Bioanalysis
Develop fit-for-purpose methods for candidates, metabolites, biomarkers, and biological activity.
Learn More
Safety Assessment
Identify early safety, tolerability, and modality-specific risks before IND-enabling studies.
Learn More
You May Also Be Interested In
Discuss Your Program with Us
Share your development goals and key challenges with our experts to define the right path forward.
Frequently Asked Questions
Candidate selection is the process of choosing the optimized molecule or therapeutic candidate with the best overall profile for advancement into formal preclinical development. The decision integrates pharmacology, efficacy, DMPK, exposure-response, safety, and developability data rather than relying on a single assay or parameter. The selected candidate should meet predefined criteria linked to the target product profile and have a clear plan for addressing any remaining risks.
Lead optimization is an iterative stage in which chemistry or molecular engineering and testing are used to improve potency, selectivity, pharmacokinetics, safety, and other properties. Candidate selection occurs after a small number of optimized leads have emerged and focuses on comparing the totality of evidence to nominate the strongest development candidate. Some targeted optimization may continue if a critical liability is identified during final candidate evaluation.
The exact package depends on the therapeutic modality, indication, route of administration, and program risk. It commonly includes confirmation of potency and selectivity, mechanism of action or target engagement, efficacy in relevant models, in vitro ADME and in vivo pharmacokinetics, bioanalytical support, exposure-response analysis, and early safety or tolerability data. Developability factors such as solubility, stability, formulation feasibility, and manufacturability should also be considered where relevant.
Candidate selection requires evaluating the quality, reproducibility, and biological relevance of each dataset rather than treating all results equally. Additional confirmatory studies may be used to resolve important inconsistencies, particularly when pharmacology, exposure, efficacy, or safety findings lead to different conclusions. The final decision should document how conflicting evidence was weighted and why the selected candidate offers the strongest overall profile.
PK/PD analysis links drug exposure to target engagement, biomarker response, or efficacy over time. This relationship helps identify the exposure associated with the desired pharmacological effect and whether that exposure is achievable within an acceptable safety margin. The results can strengthen candidate ranking and support dose, regimen, and study-design decisions for subsequent development.
Early safety testing should be driven by the candidate's modality, target biology, anticipated clinical route, and known liabilities. Depending on the program, it may include off-target profiling, in vitro cytotoxicity, genetic toxicology screens, safety pharmacology endpoints, cytokine release or immunological risk assays, and exploratory tolerability studies. These studies are generally designed for risk identification and candidate differentiation rather than to replace the definitive GLP studies required later.
Yes. Small molecules may require particular attention to metabolic stability, permeability, drug-drug interaction potential, and reactive metabolites, whereas biologics may require assessment of target-mediated disposition, immunogenicity risk, tissue cross-reactivity, or cytokine release. Oligonucleotides, peptides, conjugates, and targeted protein degraders present additional modality-specific bioanalytical, distribution, metabolism, and safety considerations. The decision framework should therefore remain consistent while the assays and acceptance criteria are tailored to the modality.
After nomination, coordinated IND-enabling studies address definitive pharmacology, DMPK, bioanalysis, and toxicology.